Deal Watch: Emergent Strikes Again, Acquiring Adapt And Its Opioid Overdose Drug For $635m
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.